Molecular pathways and agents for lowering LDL-cholesterol in addition to statins
- 12 March 2010
- journal article
- review article
- Published by Elsevier BV in Pharmacology & Therapeutics
- Vol. 126 (3), 263-278
- https://doi.org/10.1016/j.pharmthera.2010.02.006
Abstract
No abstract availableKeywords
This publication has 195 references indexed in Scilit:
- Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptorBiochemical Journal, 2009
- Activation of peroxisome proliferator‐activated receptor‐α in mice induces expression of the hepatic low‐density lipoprotein receptorBritish Journal of Pharmacology, 2008
- PCSK9 and LDL cholesterol: unravelling the target to design the bulletTrends in Biochemical Sciences, 2008
- Effect of Ezetimibe on the Prevention and Dissolution of Cholesterol GallstonesGastroenterology, 2008
- Beyond High-Density Lipoprotein Cholesterol Levels: Evaluating High-Density Lipoprotein Function as Influenced by Novel Therapeutic ApproachesJournal of the American College of Cardiology, 2008
- The Cholesterol Absorption Inhibitor Ezetimibe Acts by Blocking the Sterol-Induced Internalization of NPC1L1Cell Metabolism, 2008
- Identification of a VLDL-induced, FDNPVY-independent internalization mechanism for the LDLRThe EMBO Journal, 2007
- The Role of Coenzyme Q10 in Statin-Associated MyopathyJournal of the American College of Cardiology, 2007
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseNew England Journal of Medicine, 2006
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003